{"filing":{"accession_number":"0001104659-26-076058","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"tm2618195d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926076058/tm2618195d1_8k.htm"},"events":[{"id":12558,"run_id":11137,"accession_number":"0001104659-26-076058","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Traws Pharma announced its intention to resubmit an updated toxicology data package to the UK's MHRA for tivoxavir marboxil (TXM), a clinical-stage antiviral candidate, to enable a Phase 2a human influenza challenge study to proceed. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the resubmission and anticipated MHRA approval are critical to advancing the company's lead program. While not a specific named event type, this disclosure centers on a material operational/regulatory development affecting the company's clinical pipeline and strategy.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9439,"accession_number":"0001104659-26-076058","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Traws Pharma announced its intention to resubmit an updated toxicology data package to the UK's MHRA for tivoxavir marboxil (TXM), a clinical-stage antiviral candidate, to enable a Phase 2a human influenza challenge study to proceed. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the resubmission and anticipated MHRA approval are critical to advancing the company's lead program. While not a specific named event type, this disclosure centers on a material operational/regulatory development affecting the company's clinical pipeline and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:01:23.383765+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9439,"accession_number":"0001104659-26-076058","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Traws Pharma announced its intention to resubmit an updated toxicology data package to the UK's MHRA for tivoxavir marboxil (TXM), a clinical-stage antiviral candidate, to enable a Phase 2a human influenza challenge study to proceed. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the resubmission and anticipated MHRA approval are critical to advancing the company's lead program. While not a specific named event type, this disclosure centers on a material operational/regulatory development affecting the company's clinical pipeline and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:01:23.383765+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-06-22"}]}